Finance

Beta
Lists
XVIPF:OTCMKTS
Xvivo Perfusion AB
$29.39
0.00%
(0.00) 1D
May 19, 9:30:05 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XVIPF...
Mkt. cap
8.85B
Avg. vol.
0.00
Volume
0.00
52-wk high
$30.95
52-wk low
$16.98
Beta
1.75
Shares outstanding
31.50M
No. of employees
199
Mkt. cap
8.85B
Avg. vol.
0.00
Volume
0.00
52-wk high
$30.95
52-wk low
$16.98
Beta
1.75
Shares outstanding
31.50M
No. of employees
199
News stories
From sources across the web
About Xvivo Perfusion AB
CEOChristoffer Rosenblad
Employees199
Founded1998
Headquarters-
SectorMedical device
Websitexvivogroup.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
178.30M
189.14M
226.14M
240.96M
Cost of goods sold
45.64M
46.75M
62.07M
69.92M
Cost of revenue
45.64M
46.75M
62.07M
69.92M
Research and development expenses
31.90M
31.45M
31.34M
36.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
94.24M
92.31M
93.33M
102.89M
Operating expense
125.57M
124.48M
121.22M
139.09M
Total operating expenses
171.21M
171.23M
183.28M
209.01M
Operating income
7.08M
17.91M
42.86M
31.94M
Other non operating income
-
-
12.39M
1.00K
EBT including unusual items
-3.34M
14.76M
41.19M
42.83M
EBT excluding unusual items
-3.34M
11.65M
43.88M
42.83M
Income tax expense
-4.92M
10.42M
9.54M
6.53M
Effective tax rate
147.04%
70.61%
23.17%
15.24%
Other operating expenses
-567.00K
725.00K
-3.46M
-582.00K
Net income
1.57M
4.34M
31.65M
36.30M
Net profit margin
0.88%
2.29%
13.99%
15.06%
Earnings per share
0.04
0.13
1.01
1.15
Interest and investment income
-
-
58.59M
10.88M
Interest expense
-10.43M
-6.26M
-
-
Net interest expenses
-10.43M
-6.26M
58.59M
10.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
16.02M
40.91M
57.13M
45.78M
Gain or loss from assets sale
-
-
207.00K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer